Company description

Allucent is a global biopharmaceutical services company focused on supporting small and mid-size biotech and pharmaceutical organisations across the drug development lifecycle. The company provides integrated clinical, regulatory and consulting services designed to help sponsors navigate complex development pathways and bring innovative therapies to market more efficiently.

The company was established under the Allucent brand in 2022 through the merger of multiple specialised service providers, creating a unified global CRO focused on supporting emerging biopharma innovators. The name “Allucent” is derived from Latin, meaning to “shine a light” or create opportunity, reflecting the company’s mission to accelerate breakthrough therapies for patients with unmet medical needs.

Headquartered in Cary, North Carolina, Allucent operates globally with teams across multiple regions and supports multi-regional clinical trials and regulatory programmes. The company leverages over 30 years of combined industry experience in regulatory strategy, clinical operations and drug development.

Allucent positions itself as a science-centric CRO with a flexible, collaborative model designed specifically for small and mid-size biopharma companies. Its services span early development through post-approval, with strong expertise in oncology, neuroscience, infectious diseases, rare diseases and advanced therapies.

Key products and services

Clinical development services

• Phase I–IV clinical trial management
• Global clinical operations and study execution
• Decentralised and hybrid clinical trial delivery
• Patient recruitment and site management

Regulatory strategy and consulting

• Regulatory pathway planning and strategy
• Health authority interactions and submissions
• Clinical development planning and regulatory support

Biometrics and data services

• Biostatistics and statistical programming
• Data management and analytics
• Clinical data strategy and reporting

Clinical pharmacology and medical services

• Clinical pharmacology and modelling
• Medical monitoring and scientific oversight
• Clinical programme design and optimisation

Therapeutic expertise

• Oncology and hematology
• Neuroscience and rare diseases
• Infectious diseases
• Cell and gene therapy
• Advanced therapeutic modalities

Integrated drug development solutions

• Early-phase development support
• Global trial delivery
• Post-approval and lifecycle management
• Functional service provider (FSP) models

By combining scientific expertise, regulatory knowledge and global clinical operations, Allucent supports emerging and mid-size biopharmaceutical companies in accelerating drug development and reducing risk. Its flexible, science-centric CRO model and therapeutic expertise position the company as a strategic partner for organisations developing innovative therapies across complex disease areas.